Doctor Johnson, I’m assuming “bagel nerve” is voice dictation’s little neurological pastry crime and you mean vagal/vagus nerve stimulation.
Vagus Nerve Stimulation for Mood, Stress, and “Calming the Nervous System”
1. The 15-year-old explanation
The vagus nerve is like a giant phone cable between your brain and your body. It runs from your brainstem down through your neck to your heart, lungs, stomach, intestines, liver, spleen, and other organs. It helps control “automatic” body functions: heart rate, digestion, inflammation signaling, breathing rhythm, and the shift between fight-or-flight and rest-and-digest states.
Vagus nerve stimulation, or VNS, means using electricity, vibration, sound, magnetic effects, or other energy to try to “poke” that nerve so the brain and body change their state.
The basic idea is:
“If we can gently stimulate the vagus nerve, maybe we can tell the brain: calm down, regulate inflammation, improve mood circuits, reduce pain, or rebalance the autonomic nervous system.”
That idea is real. The annoying part, because naturally humanity had to make it murky, is that not every consumer gadget that says “vagus nerve” actually proves it is stimulating the vagus nerve in a clinically meaningful way.
2. Three very different categories
A. Implanted medical VNS
This is the serious medical version. A surgeon places a small pulse generator in the chest, like a pacemaker, with a wire wrapped around the left cervical vagus nerve in the neck. It sends programmed electrical pulses to the nerve, which then sends signals into the brainstem and onward to mood/seizure networks. CMS describes the device as a pulse generator under the left chest skin with a lead connected to the left vagus nerve, sending signals to the brain.
This version has FDA-approved uses. The FDA approved VNS for epilepsy in 1997 and for resistant depression in 2005.
For depression, the FDA indication is very specific: adjunctive long-term treatment of chronic or recurrent depression in adults having a major depressive episode who have not responded adequately to four or more adequate antidepressant treatments.
B. Prescription non-invasive cervical VNS
This is a handheld device placed on the side of the neck, usually over the carotid sheath/vagus region. The best-known is gammaCore, from electroCore. It is FDA-cleared for headache disorders, not as an over-the-counter depression treatment. gammaCore describes itself as FDA-cleared non-invasive VNS for migraine and cluster headache relief.
The FDA De Novo summary for gammaCore covered acute treatment of pain associated with episodic cluster headache in adults and says prescription use only.
C. Consumer / wellness / over-the-counter “vagus nerve” devices
These include things like Truvaga, Pulsetto, Nurosym, Sensate, Apollo-like wearables, and other devices marketed for stress, sleep, focus, relaxation, anxiety, or “nervous system regulation.”
Some may use electrical stimulation at the neck or ear. Others use vibration, sound, or haptic stimulation and imply vagal activation indirectly. This is where the evidence becomes a swamp wearing a lab coat.
Truvaga markets handheld vagus nerve stimulators for feeling calmer, clearer, and sleeping better. Pulsetto markets a neck-worn VNS device and cites a 2025 40-person study with stress and sleep claims. Sensate describes a sound/infrasonic approach meant to support vagus nerve activation.
The key distinction: marketing claims are not the same as FDA approval for mood disorders.
3. How VNS might affect mood
The vagus nerve sends sensory information from the body into the brainstem, especially the nucleus tractus solitarius. From there, signals can influence the locus coeruleus, raphe nuclei, limbic system, prefrontal cortex, amygdala, and other circuits involved in arousal, mood, attention, anxiety, and stress regulation. Reviews describe VNS as affecting brain regions and neurotransmitter systems involved in depression, including noradrenergic and serotonergic pathways.
In kid-language:
Imagine the brain has a “panic thermostat.”
The vagus nerve is one of the wires going into that thermostat.
Stimulating the wire might help turn down over-arousal, improve emotional recovery, and nudge mood circuits toward steadier functioning.
But the details matter:
| Question | Why it matters |
| Where is stimulation applied? | Neck, ear, implanted nerve cuff, chest vibration, etc. are not equivalent. |
| Is the vagus nerve actually being stimulated? | Some devices assume this more than they prove it. |
| Dose? | Frequency, pulse width, current, duration, schedule. Tiny changes may matter. |
| Condition? | Depression, anxiety, insomnia, migraine, epilepsy, Long COVID, and wellness stress are not the same target. |
| Study design? | Sham-controlled trials matter because placebo effects in neurostimulation are enormous. Naturally, the brain enjoys making fools of us. |
4. Evidence for implanted VNS in depression
FDA status
Implanted VNS is FDA-approved for difficult-to-treat depression under the narrow indication above.
Early randomized trial: not a slam dunk
A major 2005 randomized controlled trial by Rush et al. studied implanted VNS in treatment-resistant depression. The PubMed conclusion states that the study did not yield definitive evidence of short-term efficacy for adjunctive VNS.
Translation: early implanted VNS did not look like “plug it in and depression vanishes.” It looked more like a slow neuromodulation treatment that might require months and may help some patients, especially long-term.
Longer-term observational evidence
A 5-year observational study by Aaronson et al. compared treatment-resistant depression patients receiving VNS plus usual treatment versus usual treatment alone. PubMed summarizes that the VNS group had better clinical outcomes, including a significantly higher 5-year response rate.
A summary of that study reports response rates of 67.6% with VNS plus usual care versus 40.9% with usual care alone over five years.
RECOVER trial, newer evidence
The RECOVER trial was a 12-month, multicenter, double-blind, sham-controlled trial of 493 adults with marked treatment-resistant major depression. A later analysis noted the primary symptom outcome did not statistically separate the treatment groups, although quality-of-life and functional outcomes appeared clinically meaningful.
So the honest conclusion:
Implanted VNS has legitimate FDA approval and real evidence, but it is not a simple or universally dramatic antidepressant. It appears slow, adjunctive, and most relevant for severe treatment-resistant depression.
5. Evidence for non-invasive VNS / taVNS in mood
What is taVNS?
Transcutaneous auricular vagus nerve stimulation, or taVNS, stimulates parts of the outer ear thought to contain branches of the vagus nerve, especially the cymba conchae/tragus region. It is non-surgical and often uses an ear clip or electrode.
Major depressive disorder studies
A 2016 study by Rong et al. reported that taVNS appeared promising, safe, and cost-effective for mild and moderate major depressive disorder.
A 2023 meta-analysis by Tan et al. included 12 studies and 838 participants. It found taVNS significantly reduced depression scores, but the evidence quality was rated low to very low, and subgroup sample sizes were small.
That is the right scientific posture: promising, but not “case closed.”
Mood recovery study
A 2021 study found that non-invasive VNS boosted mood recovery after prolonged effort exertion, suggesting possible acute effects on mood regulation and motivation.
Post-stroke depression
Recent work includes randomized sham-controlled research on taVNS for post-stroke depression, including a 2024 double-blind randomized placebo-controlled trial cited in a 2026 review.
Insomnia, stress, and mood-adjacent effects
A 2024 randomized clinical trial in JAMA Network Open investigated taVNS for chronic insomnia and found results suggesting it was safe and effective for chronic insomnia.
This matters because sleep and mood are Siamese twins joined at the nervous system. But insomnia improvement is not the same as proving direct antidepressant efficacy.
6. Consumer devices available over-the-counter or direct-to-consumer
1. Truvaga
Truvaga is sold as a handheld vagus nerve stimulator for stress, calm, clarity, and sleep. It comes from electroCore’s ecosystem, related to gammaCore technology, but Truvaga is marketed as a wellness device rather than a prescription depression treatment. electroCore lists gammaCore, Truvaga, and Tac-Stim among its products.
Evidence level: plausible technology lineage; wellness claims; not FDA-cleared as a depression treatment based on the sources found.
2. Pulsetto
Pulsetto is a neck-worn consumer device marketed for stress, sleep, anxiety symptoms, and burnout-style complaints. It claims a 2025 study of 40 people using it twice daily for 4 weeks showed stress reduction and sleep improvement.
Evidence level: company-cited small study; not the same as large independent sham-controlled depression trials.
3. Nurosym
Nurosym markets itself around targeted electrical signals to the vagus nerve and claims improved vagus nerve activity and heart-rate variability.
Evidence level: research-facing claims exist, but claims should be separated from proof that it treats mood disorders.
4. Sensate
Sensate is more of a vibration/sound-based calming device. It says its mix of infrasonic frequencies and sound helps activate or support vagal pathways. A ClinicalTrials.gov entry exists for Sensate II utilization and perceived stress, but that is not the same thing as a completed, definitive depression-treatment trial.
Evidence level: stress/wellness concept; weak direct evidence for clinical vagal stimulation or mood-disorder treatment.
5. gammaCore
gammaCore is a prescription non-invasive cervical VNS device, not casual OTC. It is FDA-cleared for migraine and cluster headache indications.
Evidence level: stronger regulatory footing, but for headache indications, not mood modification.
7. Safety issues, because electricity near the neck is not aromatherapy
VNS affects autonomic tone, and the vagus nerve has relationships with heart rate and rhythm. Consumer products usually warn against use in people with implanted electrical devices, arrhythmias, serious heart disease, pregnancy, seizure disorders unless supervised, or neck surgery/vascular disease, depending on product.
There are real-world adverse event reports. For example, an FDA MAUDE report describes palpitations and frequent ventricular arrhythmias after Pulsetto use, though MAUDE reports do not prove causation.
Practical caution:
- Do not use neck electrical stimulation over the carotid sinus casually in someone with arrhythmia risk.
- Avoid stacking devices with pacemakers, defibrillators, implanted stimulators, or uncertain cardiac status.
- Mood disorders deserve real care; don’t replace psychiatric treatment with a gadget because the ad copy discovered the word “parasympathetic.”
8. Bottom-line conclusions
What is well-supported?
Implanted VNS is real medicine. It is FDA-approved for severe treatment-resistant depression under specific criteria. It has mixed short-term evidence but stronger long-term observational and newer functional/QOL evidence.
What is promising but not settled?
taVNS, especially auricular stimulation, has peer-reviewed studies and meta-analyses suggesting possible antidepressant and mood-regulating effects, but evidence quality is still limited.
What is most overmarketed?
Consumer “vagus nerve” wellness devices. Some may help stress or sleep subjectively. Some may truly stimulate vagal pathways. But many claims outrun the evidence, because apparently selling nervous-system enlightenment in a rechargeable pebble is now an industry.
Best simple summary
VNS is real.
Implanted VNS has medical approval for severe resistant depression.
Ear/neck non-invasive VNS has promising research.
OTC wellness gadgets may help some people relax, but they are not proven depression treatments.
The gap between “stimulates the vagus nerve” and “treats mood disorder” is large enough to park a pharmaceutical sales conference in it.
